Modi S - Search Results

1

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.

Modi S, Stopeck AT, Gordon MS, Mendelson D, Solit DB, Bagatell R, Ma W, Wheler J, Rosen N, Norton L, Cropp GF, Johnson RG, Hannah AL, Hudis CA. Modi S, et al. J Clin Oncol. 2007 Dec 1;25(34):5410-7. doi: 10.1200/JCO.2007.11.7960. J Clin Oncol. 2007. PMID: 18048823 Clinical Trial.

2

Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer.

Modi S, Panageas KS, Duck ET, Bach A, Weinstock N, Dougherty J, Cramer L, Hudis C, Norton L, Seidman A. Modi S, et al. J Clin Oncol. 2002 Sep 1;20(17):3665-73. doi: 10.1200/JCO.2002.08.057. J Clin Oncol. 2002. PMID: 12202668 Clinical Trial.

3

Single-agent gemcitabine in the treatment of advanced breast cancer.

Modi S, Seidman AD. Modi S, et al. Clin Breast Cancer. 2004 Jan;4 Suppl 3:S101-6. doi: 10.3816/cbc.2004.s.002. Clin Breast Cancer. 2004. PMID: 14754466 Review.

4

A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.

Modi S, Seidman AD, Dickler M, Moasser M, D'Andrea G, Moynahan ME, Menell J, Panageas KS, Tan LK, Norton L, Hudis CA. Modi S, et al. Breast Cancer Res Treat. 2005 Mar;90(2):157-63. doi: 10.1007/s10549-004-3974-0. Breast Cancer Res Treat. 2005. PMID: 15803362 Clinical Trial.

5

A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane.

Modi S, Currie VE, Seidman AD, Bach AM, Panageas KS, Theodoulou M, Moasser MM, D'Andrea GM, Lake DE, Choi J, Norton L, Hudis CA. Modi S, et al. Clin Breast Cancer. 2005 Apr;6(1):55-60. doi: 10.3816/CBC.2005.n.009. Clin Breast Cancer. 2005. PMID: 15899073 Clinical Trial.

6

Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane.

Fornier MN, Modi S, Panageas KS, Norton L, Hudis C. Fornier MN, et al. Among authors: modi s. Cancer. 2005 Oct 15;104(8):1575-9. doi: 10.1002/cncr.21385. Cancer. 2005. PMID: 16134178 Free article.

7

Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer.

Modi S, DiGiovanna MP, Lu Z, Moskowitz C, Panageas KS, Van Poznak C, Hudis CA, Norton L, Tan L, Stern DF, Carter D, Seidman AD. Modi S, et al. Cancer Invest. 2005;23(6):483-7. doi: 10.1080/07357900500201301. Cancer Invest. 2005. PMID: 16203655

8

A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer.

Modi S, D'Andrea G, Norton L, Yao TJ, Caravelli J, Rosen PP, Hudis C, Seidman AD. Modi S, et al. Clin Breast Cancer. 2006 Aug;7(3):270-7. doi: 10.3816/CBC.2006.n.040. Clin Breast Cancer. 2006. PMID: 16942645 Clinical Trial.

9

Preoperative chemotherapy for breast cancer: miracle or mirage?

Hudis C, Modi S. Hudis C, et al. Among authors: modi s. JAMA. 2007 Dec 12;298(22):2665-7. doi: 10.1001/jama.298.22.2665. JAMA. 2007. PMID: 18073362 No abstract available.

10

The heat shock protein 90 chaperone complex: an evolving therapeutic target.

Barginear MF, Van Poznak C, Rosen N, Modi S, Hudis CA, Budman DR. Barginear MF, et al. Among authors: modi s. Curr Cancer Drug Targets. 2008 Sep;8(6):522-32. doi: 10.2174/156800908785699379. Curr Cancer Drug Targets. 2008. PMID: 18781898 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

721 results

Search Page

Filters